Invex Therapeutics Share Price and Company Fundamentals



Price
$0.605
Change
0.005 (0.833%)
52 week
0.51 - 1.1

Last traded: Yesterday at 5:22 AM

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Subiaco, Australia.

Key Metrics

PE ratio

-

PB ratio

1.38

Dividend yield

Beta

1.06

Market cap

$45.47M

Enterprise value

$11.51M

Company profile

Primary activitiesBiopharmaceuticals.
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.invextherapeutics.com
Mailing address38 Rowland Street Level 1 Subiaco WA 6008 Australia
Phone / Fax61 8 6382 0137 /
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Invex Therapeutics does not pay dividends.

Company Executives

As of Jul 2021, following are the company executives and directors listed on Invex Therapeutics.

NameTitleAgeTotal Pay
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLBCFO & Company Sec.142.92k
Prof. Alexandra Jean SinclairExec. Director & Chief Scientific Officer152.92k

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

0.00%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Invex Therapeutics is 45.47M and its enterprise value is 11.51M.

The IXC's stocks Beta value is 1.06 making it 6% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Invex Therapeutics (IXC)

Invex Therapeutics (ASX:IXC) Frequently Asked Questions

1. What is Invex Therapeutics's Stock Symbol?

Invex Therapeutics trades on ASX under the ticker symbol "IXC".

2. What is Invex Therapeutics's stock price today?

One share of IXC stock can currently be purchased for approximately $0.605.

3. How can I contact Invex Therapeutics?

Invex Therapeutics's mailing address is 38 Rowland Street Level 1 Subiaco WA 6008 Australia. The company can be reached via phone at 61 8 6382 0137.

4. What is Invex Therapeutics's official website?

The official website of Invex Therapeutics is http://www.invextherapeutics.com.

5. Which share registry manages Invex Therapeutics's stock?

Invex Therapeutics's stock is managed by AUTOMIC REGISTRY SERVICES.